

# What to Know About Schizophrenia

Schizophrenia is a chronic, progressive and severely debilitating mental disorder that affects how one thinks, feels and acts. Patients experience many symptoms, including delusions, hallucinations, disorganized speech or behavior and impaired cognitive ability.<sup>1</sup>

**~24**  
million worldwide



**3.5**  
million in the U.S.



Approximately **24 million** people worldwide and **3.5 million** people in the U.S. are currently diagnosed with schizophrenia.<sup>2</sup>

**Early 20s**  
for men




**Late 20s**  
for women



Although schizophrenia can occur at any age, the average age of onset tends to be in the **late teens to early 20s for men**, and **late 20s to early 30s for women**.<sup>3</sup>

In epidemiological surveys, approximately **40% of the respondents with schizophrenia** report that they **have not** received any mental health treatments in the preceding 6–12 months.<sup>4</sup>



Relapse continues to be an ongoing and complex challenge faced by many schizophrenia patients, with rates estimated to be between **50-92%** globally.<sup>5</sup>



## EACH RELAPSE CARRIES A BIOLOGICAL RISK, INCLUDING:



Changes in  
brain morphology



Loss of day-to-day  
function



Treatment  
resistance

**REFERENCES:** 1. Substance Abuse and Mental Health Services Administration. Schizophrenia. <https://www.samhsa.gov/mental-health/schizophrenia>. Accessed November 2023. Velligan DI, Rao S. The epidemiology and global burden of schizophrenia. J Clin Psychiatry. 2023;84(1):MS21078COM5. <https://doi.org/10.4088/JCP.MS21078COM5>. Wander C. (2020). Schizophrenia: opportunities to improve outcomes and reduce economic burden through managed care. The American journal of managed care, 26(3 Suppl), S62–S68. <https://doi.org/10.37765/ajmc.2020.43013> 2. Velligan DI, Rao S. The epidemiology and global burden of schizophrenia. J Clin Psychiatry. 2023;84(1):MS21078COM5. <https://doi.org/10.4088/JCP.MS21078COM5>. Wander C. (2020). Schizophrenia: opportunities to improve outcomes and reduce economic burden through managed care. The American journal of managed care, 26(3 Suppl), S62–S68. <https://doi.org/10.37765/ajmc.2020.43013> World Health Organization. (n.d.). Schizophrenia. World Health Organization. <https://www.who.int/news-room/fact-sheets/detail/schizophrenia> 3. Substance Abuse and Mental Health Services Administration. Schizophrenia. <https://www.samhsa.gov/mental-health/schizophrenia>. Accessed November 2023. 4. Mojtabai R, Fochtmann L, Chang SW, Kotov R, Craig TJ, Bromet E. Unmet need for mental health care in schizophrenia: an overview of literature and new data from a first-admission study. Schizophr Bull. 2009 Jul;35(4):679–95. doi: 10.1093/schbul/sbp045. Epub 2009 Jun 8. PMID: 19505994; PMCID: PMC2696378. 5. Emsley, R., & Kilian, S. (2018). Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review. Neuropsychiatric disease and treatment, 14, 205–223. Emsley, R., Chiliza, B., Asmal, L. et al. (2013) The nature of relapse in schizophrenia. BMC Psychiatry 13, 50. Andreasen, N. C., et al. (2013). Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. The American journal of psychiatry, 170(6), 609–615.